TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05698771

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR)
Description: The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects . A total of 6 healthy individuals (3 men and 3 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using spectroscopic assays. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nicotinamide mononucleotide
Description: The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects. A total of 6 healthy individuals (3 men and 3 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using spectroscopic assays. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR)
Description: A total of n=6 healthy individuals (3 men and 3 women) will receive NR 1200 mg per day for 4 weeks, followed by 3 weeks of washout. The individuals will undergo repeated blood sampling and 31P-MRS brain scans once per week during the 7 weeks period, Blood will be analyzed for NAD-metabolites using spectroscopic assays.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR)
Description: A total of n=6 individuals with Parkinson's disease (3 men and 3 women) will receive NR 1200 mg per day for 4 weeks, followed by 3 weeks of washout. The individuals will undergo repeated blood sampling and 31P-MRS brain scans once per week during the 7 weeks period, Blood will be analyzed for NAD-metabolites using spectroscopic assays.
Study: NCT05881005

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: hepatic MRI
Description: Quantification of hepatic steatosis with RMI at the diagnosis (T0) and one year after remission (T1). The percentage of patients with complete resolution of hepatic steatosis on MRI will be determined.
Study: NCT05933252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality (AR)
Description: an app on an iPad every 15 minutes
Study: NCT06033950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: Oral finerenone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo.
Study: NCT04881240

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR(Mem) T-cells
Description: Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR(Mem) T-cells
Description: Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.
Study: NCT04909970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Description: Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Control (Waiting list)
Description: Usual practice during the first 16 weeks. At the end of study, the participant will practice Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
Study: NCT06434506

Intervention type: OTHER
Intervention: no intervention
Description: No intervention
Study: NCT06478745

Intervention type: OTHER
Intervention: Retrospective and prospective cohort
Description: * Retrospective study: Population-based retrospective cohort study with RWD. Patients ≥60 years old with 2 or more chronic diseases diagnosed before 01/01/2012, users of the public health system of the participating Autonomous Communities, will be included. Those who have had no contact with primary care defined as contact in a medical or nursing consultation in the previous two years (2010-2012) will be excluded.~* Prospective longitudinal observational open cohort study developed in the context of the MULTIPAP and LOXO studies.Patients over 65 years of age with multimorbidity (3 or more chronic pathologies) and polypharmacy (5 or more drugs taken during at least the last 3 months before inclusion in the study) under follow-up from primary care in Madrid, Aragon and Andalusia.

Intervention type: OTHER
Intervention: Focus group, semi-structured interviews and Photovoice
Description: The participants will be people with multimorbidity over 60 years of age recruited from Primary Care centers in Spain. A theoretical sampling will be carried out. Data will be collected through video and audio recordings from a total of 16 focus groups and 20 interviews in 7 regions, and will finally be transcribed for a triangulated thematic analysis. Two groups will be carried out with participation-action research methodology - Photovoice.

Intervention type: OTHER
Intervention: Systematic review
Description: No patient recruitment required
Study: NCT04608448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin Topical Ointment
Description: 8% topical rapamycin ointment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Petrolatum ointment containing no active ingredient
Study: NCT04847401

Intervention type: DIAGNOSTIC_TEST
Intervention: H. pylori stool antigen
Description: using H. pylori antigen kits in stool

Intervention type: DIAGNOSTIC_TEST
Intervention: H. pylori stool antigen
Description: using H. pylori antigen kits in stool
Study: NCT05121194

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behaviour Therapy
Description: Group-based cognitive behaviour therapy (CBT) is an evidence-based treatment that allows service providers to interact with high volumes of individuals who need mental health support. CBT is the most well-researched and well-recognized of all psychotherapies, and is often considered the gold-standard in psychotherapy treatment. While CBT has shown efficacy in the treatment of a range of mental and substance use disorders, it has also been shown to be useful in building resiliency, being used as a tool to better cope during stressful life situations even among individuals who do not have an existing mental illness. Furthermore, research suggests that gains achieved in mental health during CBT are maintained long after treatment completion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behaviour Therapy
Description: Group-based cognitive behaviour therapy (CBT) is an evidence-based treatment that allows service providers to interact with high volumes of individuals who need mental health support. CBT is the most well-researched and well-recognized of all psychotherapies, and is often considered the gold-standard in psychotherapy treatment. While CBT has shown efficacy in the treatment of a range of mental and substance use disorders, it has also been shown to be useful in building resiliency, being used as a tool to better cope during stressful life situations even among individuals who do not have an existing mental illness. Furthermore, research suggests that gains achieved in mental health during CBT are maintained long after treatment completion.
Study: NCT05060315

Intervention type: COMBINATION_PRODUCT
Intervention: Remunity Pump for Remodulin
Description: Participants on the study will receive Remodulin via the Remunity Pump with dosing and titration managed at the discretion of the prescribing healthcare professional. Dosing and titration of Remodulin will in no way be influenced by the participation in this study or this protocol.
Study: NCT05123443

Intervention type: BIOLOGICAL
Intervention: Blood sample provided
Description: Individuals who consent to provide a blood sample will be included in the cross-sectional genetics study.

Intervention type: DIAGNOSTIC_TEST
Intervention: 7-T MRI scan
Description: Individuals who consent to receive an additional 7-T MRI scan will be invited to the Sir Peter Mansfield Imaging Centre. This current MRI will be compared against the baseline 7-T scan performed between 2008 - 2012.
Study: NCT05646316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05909891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient training
Description: A training booklet will be created by scanning the literature on iron deficiency anemia. The training booklet will be evaluated in terms of content and readability, according to the DISCERN measurement tool, while obtaining expert opinion.~The training period will be at least 35-40 minutes, taking into account the educational status of the patient and explaining the importance of compliance with the treatment. After the training, when the patients come to the routine check-ups in the 1st and 2nd months, the level of compliance with the treatment and the fatigue of the patients will be evaluated.
Study: NCT05402436

Intervention type: OTHER
Intervention: A diagnosis of atypia as part of the English screening programme
Description: An atypia diagnosis of either ADH (including AIDEP), LISN (both ALH and LCIS) or FEA
Study: NCT06053619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GaitTrainer and Virtual Reality
Description: Realization of Gait Trainer-assisted robot walking rehabilitation sessions without and with the addition of an immersive VR device. The proposed virtual stage will be a natural space (i.e. forest) of 360°. The subject will be able to explore the environment without moving. The created scene represents a straight path crossing a landscape composed of different natural elements. A fluid movement is obtained with the help of two sensors (trackers) of the HTC Vive device, placed at the level of the subject's feet. Moreover, thanks to these sensors the individual has a virtual representation of his lower limbs.~Post-stroke patients will perform 3 conventional sessions (Gait Trainer alone) and 3 sessions with the immersive VR device (Gait Trainer + VR).
Study: NCT06284694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: See experimental arm description
Study: NCT05715086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopy
Description: Upfront ureteroscopy
Study: NCT05490875

Intervention type: PROCEDURE
Intervention: Carotid ultrasound
Description: Carotid ultrasound will be done to both sides of the neck to look at the carotid arteries.

Intervention type: OTHER
Intervention: Blood draw
Description: This optional blood draw could occur anytime from the time of enrollment on the study until 90 days after the research ultrasound.

Intervention type: OTHER
Intervention: Survey
Description: Participants will complete a 15-minute survey about how acceptable participants find the ultrasound procedure, whether participants would be open to it in the future if a doctor thought it was necessary, whether participants would be open to getting treatment for artery problems, and how participants feel about their own risk of stroke.
Study: NCT06052072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gradient Denervation System
Description: Pulmonary artery denervation (PADN) procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.
Study: NCT05622968

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Insertion of 18G Foley catheter into the cervical canal and inflating the balloon to 60 mls using sterile water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravaginal prostaglandin E2
Description: Insertion of intravaginal Dinoprostone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravaginal prostaglandin E2
Description: Insertion of intravaginal Dinoprostone
Study: NCT04934293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Before proton therapy, virtual reality sessions will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Before proton therapy, virtual reality sessions will be performed.
Study: NCT04735393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
Study: NCT05348785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB122-Matching Placebo
Description: Administered as specified in the treatment arm
Study: NCT06242197

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: written advice
Description: written advice (in leaflet form) was given to CRC patients to give to first degree relatives, or send to first degree relatives directly. this leaflet contained information about cancer risk and recommended screening methods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: written advice
Description: written advice (in leaflet form) was given to CRC patients to give to first degree relatives, or send to first degree relatives directly. this leaflet contained information about cancer risk and recommended screening methods.
Study: NCT04989504

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound Dressing Material
Description: Apply Mepitel Film

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05810675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Early Intervention Program (TEIP)
Description: The Telehealth Early Intervention Program (TEIP) that will be carried out by parents at home when interact with their children; and to train parents in delivering developmental and behavioral techniques to their children. The participating families will be randomized in parallel to treatment and comparison groups for teaching the knowledge and techniques: (1) Treatment group: providing the training of TEIP for parents via telehealth modalities as they learn critical skills with their child with the goal of increasing multidimensional child developments. Intervention provider will provide the training for parent-child dyad interaction to work with parents to implement these strategies at home environment.
Study: NCT06010485

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serial Casting
Description: A short leg cast is applied to the serial casting group by an orthopedic specialist once every three days for three weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Stretching exercises, strengthening exercises, balance exercises, proprioception exercises, and heel walking exercises are applied to the physical therapy group for 3 weeks with a physiotherapist for 3 sessions a week.
Study: NCT06529211

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low caloric diet
Description: Low caloric diet: the participants will receive low caloric diet program (1500 Kcal/ day) for 6 weeks as follows: 45% carbohydrate, 20% fat and 35% proteins of total calorie intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low caloric diet
Description: Low caloric diet: the participants will receive low caloric diet program (1500 Kcal/ day) for 6 weeks as follows: 45% carbohydrate, 20% fat and 35% proteins of total calorie intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low caloric diet
Description: Low caloric diet: the participants will receive low caloric diet program (1500 Kcal/ day) for 6 weeks as follows: 45% carbohydrate, 20% fat and 35% proteins of total calorie intake.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound cavitation
Description: Ultrasound cavitation + Low caloric diet Low caloric diet program (1500 Kcal/ day): for 6 weeks.~Ultrasound cavitation: It will be on abdomen for 30 minutes/session, 2 sessions/week for 6 weeks as follows:~* The participants will be in supine lying position and the abdomen is divided into two sides right and left from the midline.~* The Ultrasound pulsed waves will be set with power input (AC100/ 240V), frequency (40 KHz), and Power output (45W). This will be for 15 minutes on each abdominal side.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole body vibration + Low caloric diet Low caloric diet program (1500 Kcal/ day) for 6 weeks.~Whole body vibration: for 30 minutes/session, 2 sessions/week for 6 weeks as follows:~* The participants will begin with a brief warm-up for 5 minutes by doing deep breathing exercises.~* Then they will stand with feet shoulder-width apart on the platform while holding handrails to maintain balance and stability. They will be instructed to relax and allow the vibrations to pass through her body. This will be applied for 20 minutes per session.~* The vibration will be started with lower settings and gradually will be increased till the desired frequency and amplitude (45 HZ) will be reached.~* After the session will be completed, the participant will be instructed to cool down gradually by doing deep breathing for 5 minutes to help their body to return to a resting state. They will be advised to drink plenty of water to be hydrated and recovered after the WBV session.
Study: NCT06366958

Intervention type: PROCEDURE
Group type: OTHER
Intervention: excision of dorsal wrist ganglion
Description: open and arthroscopic excision of dorsal wrist ganglion